arrow
Back
A

Andrew J. Leidner

National Center for Immunization and Respiratory Diseases

20H-index
72Paper Count
2.6KCitation Count
Published Papers 27
Publication Date
COVID-19–Related Healthcare Utilization and Costs in a Large Insured US Population, 2021–2025
err2026-07-26
err0
PREAI
errXiaoyu Dong; Andrew J. Leidner; Jamison Pike; Bo-Hyun Cho; Megan Wallace; Fangjun Zhou
errShare
errSave
Public health impact and cost-effectiveness of 20-valent pneumococcal conjugate vaccine use among children in the United States
errVaccine
IF3.5
err2026-01-20
err0
PREAI
errDiepreye Ayabina; Charles Stoecker; Bo-Hyun Cho; Namrata Prasad; Laura M. King; Andrew J. Leidner; Miwako Kobayashi
errShare
errSave
Cost-effectiveness of age-based and risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults
errVaccine
IF3.5
err2025-11-21
err0
PREAI
errCharles Stoecker; Yin Wang; Andrew J. Leidner; Bo-Hyun Cho; Cheryl Ward; Miwako Kobayashi
errShare
errSave
Cost-effectiveness of pentavalent meningococcal (MenABCWY) vaccination among adolescents in the United States
errVaccine
IF3.5
err2025-07-08
err0
PREAI
errXiaoyu Dong; Sarah F. Schillie; Lucy Alexandra McNamara; Andrew J. Leidner
errShare
errSave
Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness
err2024-11-25
err0
PREAI
errHutton, David W.; Prosser, Lisa A.; Rose, Angela M.; Mercon, Kerra; Ortega-Sanchez, Ismael R.; Leidner, Andrew J.; McMorrow, Meredith L.; Fleming-Dutra, Katherine E.; Prill, Mila M.; Pike, Jamison; Jones, Jefferson M.
errShare
errSave
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
err2024-11-25
err4
PREAI
errHutton, David W.; Prosser, Lisa A.; Rose, Angela M.; Mercon, Kerra; Ortega-Sanchez, Ismael R.; Leidner, Andrew J.; McMorrow, Meredith L.; Fleming-Dutra, Katherine E.; Prill, Mila M.; Pike, Jamison; Jones, Jefferson M.
errShare
errSave
Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years
err2023-02-01
err3
errOAAI
errLeidner, Andrew J.; Anderson, Tara C.; Hong, Kai; Ortega-Sanchez, Ismael R.; Guo, Angela; Pike, Jamison; Prosser, Lisa A.; Dooling, Kathleen L.
errShare
errSave
Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults
err2022-04-27
err3
errOAAI
errJanusz, Cara B.; Anderson, Tara C.; Leidner, Andrew J.; Lee, Grace M.; Dooling, Kathleen; Prosser, Lisa A.
errShare
errSave
Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices-United States, 2022
err2022-03-01
err6
PREAI
errAnderson, Tara C.; Masters, Nina B.; Guo, Angela; Shepersky, Leah; Leidner, Andrew J.; Lee, Grace M.; Kotton, Camille N.; Dooling, Kathleen L.
errShare
errSave
Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines
err2022-02-09
err2
errOAAI
errPike, Jamison; Leidner, Andrew J.; Chesson, Harrell; Stoecker, Charles; Grosse, Scott D.
errShare
errSave
Cost-effectiveness of dengue vaccination in Puerto Rico
err2021-07-26
err11
errOAAI
errEspana, Guido; Leidner, Andrew J.; Waterman, Stephen H.; Perkins, T. Alex
errShare
errSave
Societal Costs of a Measles Outbreak
err2021-04-01
err11
errOAAI
errPike, Jamison; Melnick, Alan; Gastanaduy, Paul A.; Kay, Meagan; Harbison, Jeff; Leidner, Andrew J.; Rice, Samantha; Asato, Kennly; Schwartz, Linda; DeBolt, Chas
errShare
errSave
A review of the cost-effectiveness of adult influenza vaccination and other preventive services
err2019-09-01
err23
errOAAI
errDabestani, Nazila M.; Leidner, Andrew J.; Seiber, Eric E.; Kim, Hyoshin; Graitcer, Samuel B.; Foppa, Ivo M.; Bridges, Carolyn B.
errShare
errSave